These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 12955644)

  • 1. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
    Simonelli C; Zanussi S; Cinelli R; Dal Maso L; Di Gennaro G; D'Andrea M; Nasti G; Spina M; Vaccher E; De Paoli P; Tirelli U
    Clin Infect Dis; 2003 Sep; 37(6):820-7. PubMed ID: 12955644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
    Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
    Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
    Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
    Simonelli C; Tedeschi R; Gloghini A; Bortolin MT; Spina M; Bidoli E; Cinelli R; De Paoli P; Carbone A; Tirelli U
    Clin Infect Dis; 2005 Apr; 40(7):1022-7. PubMed ID: 15824995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.
    Fulco PP; Hynicka L; Rackley D
    Ann Pharmacother; 2010 Feb; 44(2):377-82. PubMed ID: 20040700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
    Crosswell HE; Bergsagel DJ; Yost R; Lew G
    Pediatr Blood Cancer; 2008 Apr; 50(4):883-5. PubMed ID: 17278123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
    Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
    Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated plasmablastic lymphoma.
    Sharma R; Abdou S; Plymyer MR; Rohatgi C
    J Am Coll Surg; 2004 Oct; 199(4):654-5. PubMed ID: 15454154
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
    Castillo JJ; Echenique IA
    Am J Hematol; 2012 Mar; 87(3):330-3. PubMed ID: 22308010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
    Cruciani M; Gatti G; Vaccher E; Di Gennaro G; Cinelli R; Bassetti M; Tirelli U; Bassetti D
    J Antimicrob Chemother; 2005 Apr; 55(4):546-9. PubMed ID: 15728147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
    J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.